Modified Ipilimumab Regimen Reduces Adverse Events in Patients With Renal Cancer
A UK PRISM phase 2 trial revealed that a [...]
Renal Cancer
Modified Ipilimumab Regimen Reduces Adverse Events in Patients With Renal Cancer
| Categories: oncology, renal-cancer
A UK PRISM phase 2 trial revealed that a modified regimen of ipilimumab every 12 weeks, combined with nivolumab, reduced serious adverse events in patients […]
POD1UM-101 Trial Reveals Retifanlimab’s Efficacy in Endometrial Cancer
The phase 1 POD1UM-101 trial, presented at the 2023 [...]